

Patents and biosimilars: Ensuring strong intellectual property protection

Sandra Frantzen

McAndrews, Held & Malloy, Ltd, USA

Biosimilar technologies are at the forefront of both science and the law with intellectual property issues playing a large strategic role. Understanding intellectual property issues is not always easy and biotechnologies sometimes raise challenges regarding how to manage and protect intellectual property rights. The law regarding how biotechnology can be protected is constantly evolving and it is important to keep abreast of ongoing developments. This presentation is intended to familiarize the audience with current patent issues facing those in the biosimilar space as well as legal issues presented by the Biologics Price Competition and Innovation Act.

Biography

Sandra Frantzen is an intellectual property lawyer and a partner at the firm McAndrews, Held & Malloy in Chicago. She has a degree in chemistry and graduated with honors from University of Chicago Law School. She advises clients on a broad range of intellectual property law including strategic intellectual property development, acquisition, protection and enforcement and assists clients by litigating and resolving intellectual property disputes. She practice focuses on litigation and consulting in the medical device, pharmaceutical and biotechnology industries and she has particular expertise in the America Invents Act as well as the Biologics Price Competition And Innovation Act and the advent of U.S. biosimilars.

SFRANTZEN@mcandrews-ip.com